These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24934295)

  • 1. Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.
    Kosloski MP; Shetty KA; Wakabayashi H; Fay PJ; Balu-Iyer SV
    AAPS J; 2014 Sep; 16(5):1038-45. PubMed ID: 24934295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.
    Nakajima Y; Oda A; Baatartsogt N; Kashiwakura Y; Ohmori T; Nogami K
    Blood Adv; 2024 Aug; 8(15):3929-3940. PubMed ID: 38820442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.
    Leong L; Sim D; Patel C; Tran K; Liu P; Ho E; Thompson T; Kretschmer PJ; Wakabayashi H; Fay PJ; Murphy JE
    Blood; 2015 Jan; 125(2):392-8. PubMed ID: 25331117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.
    Wakabayashi H; Fay PJ
    Biochemistry; 2013 Jun; 52(22):3921-9. PubMed ID: 23659383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.
    Gale AJ; Bhat V; Pellequer JL; Griffin JH; Mosnier LO; Von Drygalski A
    Pharm Res; 2016 Jun; 33(6):1517-26. PubMed ID: 26960296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
    Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
    J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.
    Monaghan M; Wakabayashi H; Griffiths A; Wintermute J; Fay PJ
    Thromb Haemost; 2014 Sep; 112(3):495-502. PubMed ID: 24899227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
    Lunghi B; Bernardi F; Martinelli N; Frusconi S; Branchini A; Linari S; Marchetti G; Castaman G; Morfini M
    J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.
    Hakeos WH; Miao H; Sirachainan N; Kemball-Cook G; Saenko EL; Kaufman RJ; Pipe SW
    Thromb Haemost; 2002 Nov; 88(5):781-7. PubMed ID: 12428094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.
    Shetty KA; Merricks EP; Raymer R; Rigsbee N; Nichols TC; Balu-Iyer SV
    J Pharm Sci; 2016 Aug; 105(8):2459-64. PubMed ID: 27372547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.
    Kosloski MP; Pisal DS; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2014 Apr; 35(3):154-63. PubMed ID: 24259187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
    Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
    Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational analysis of Asp519 and Glu665 mutations of coagulation factor FVIIIa: Implications for enhanced binding affinity of A2-domain.
    Shearin S; Venkateswarlu D
    J Mol Graph Model; 2017 Sep; 76():441-447. PubMed ID: 28780303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.